Orexo AB (ORX) - Net Assets

Latest as of December 2025: Skr490.60 Million SEK ≈ $52.80 Million USD

Based on the latest financial reports, Orexo AB (ORX) has net assets worth Skr490.60 Million SEK (≈ $52.80 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.30 Billion ≈ $140.20 Million USD) and total liabilities (Skr812.20 Million ≈ $87.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Orexo AB asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr490.60 Million
% of Total Assets	37.66%
Annual Growth Rate	13.72%
5-Year Change	40.33%
10-Year Change	58.11%
Growth Volatility	113.26

Orexo AB - Net Assets Trend (2002–2025)

This chart illustrates how Orexo AB's net assets have evolved over time, based on quarterly financial data. Also explore ORX total assets for the complete picture of this company's asset base.

Annual Net Assets for Orexo AB (2002–2025)

The table below shows the annual net assets of Orexo AB from 2002 to 2025. For live valuation and market cap data, see ORX market cap.

Year	Net Assets	Change
2025-12-31	Skr490.60 Million ≈ $52.80 Million	+488.44%
2024-12-31	Skr-126.30 Million ≈ $-13.59 Million	-314.43%
2023-12-31	Skr58.90 Million ≈ $6.34 Million	-69.62%
2022-12-31	Skr193.90 Million ≈ $20.87 Million	-44.54%
2021-12-31	Skr349.60 Million ≈ $37.62 Million	-37.40%
2020-12-31	Skr558.50 Million ≈ $60.10 Million	-20.94%
2019-12-31	Skr706.40 Million ≈ $76.02 Million	+48.37%
2018-12-31	Skr476.10 Million ≈ $51.24 Million	+44.67%
2017-12-31	Skr329.10 Million ≈ $35.42 Million	+6.06%
2016-12-31	Skr310.30 Million ≈ $33.39 Million	+16.45%
2015-12-31	Skr266.46 Million ≈ $28.68 Million	-41.44%
2014-12-31	Skr455.02 Million ≈ $48.97 Million	+181.82%
2013-12-31	Skr161.46 Million ≈ $17.38 Million	-15.55%
2012-12-31	Skr191.19 Million ≈ $20.58 Million	-38.54%
2011-12-31	Skr311.10 Million ≈ $33.48 Million	-33.56%
2010-12-31	Skr468.24 Million ≈ $50.39 Million	-14.66%
2009-12-31	Skr548.66 Million ≈ $59.04 Million	-3.71%
2008-12-31	Skr569.78 Million ≈ $61.32 Million	-15.12%
2007-12-31	Skr671.25 Million ≈ $72.24 Million	+106.95%
2006-12-31	Skr324.35 Million ≈ $34.91 Million	-4.30%
2005-12-31	Skr338.91 Million ≈ $36.47 Million	+326.64%
2004-12-31	Skr79.44 Million ≈ $8.55 Million	+121.38%
2003-12-31	Skr35.88 Million ≈ $3.86 Million	+40.62%
2002-12-31	Skr25.52 Million ≈ $2.75 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Orexo AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 134138200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr15.20 Million	3.10%
Other Components	Skr1.84 Billion	374.56%
Total Equity	Skr490.60 Million	100.00%

Orexo AB Competitors by Market Cap

The table below lists competitors of Orexo AB ranked by their market capitalization.

Company	Market Cap
Dynamic Medical Technologies TWO:4138	$70.45 Million
Sekar Bumi Tbk JK:SKBM	$70.46 Million
Huikwang TWO:6508	$70.48 Million
Kamdhenu Limited NSE:KAMDHENU	$70.48 Million
Island Pharmaceuticals Ltd AU:ILA	$70.44 Million
Oswal Agro Mills Limited NSE:OSWALAGRO	$70.44 Million
Gateway Real Estate AG XETRA:GTY	$70.41 Million
FALCON METALS LTD F:E47	$70.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Orexo AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -126,300,000 to 490,600,000, a change of 616,900,000.
Net loss of 129,800,000 reduced equity.
Other comprehensive income decreased equity by 32,799,999.
Other factors increased equity by 779,499,999.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-129.80 Million	-26.46%
Other Comprehensive Income	Skr-32.80 Million	-6.69%
Other Changes	Skr779.50 Million	+158.89%
Total Change	Skr-	%

Book Value vs Market Value Analysis

This analysis compares Orexo AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.33x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.02x to 1.33x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2002-12-31	Skr974.60	Skr18.86	x
2003-12-31	Skr1222.76	Skr18.86	x
2004-12-31	Skr2094.50	Skr18.86	x
2005-12-31	Skr25.52	Skr18.86	x
2006-12-31	Skr24.21	Skr18.86	x
2007-12-31	Skr44.41	Skr18.86	x
2008-12-31	Skr25.10	Skr18.86	x
2009-12-31	Skr24.14	Skr18.86	x
2010-12-31	Skr18.36	Skr18.86	x
2011-12-31	Skr11.45	Skr18.86	x
2012-12-31	Skr5.96	Skr18.86	x
2013-12-31	Skr4.98	Skr18.86	x
2014-12-31	Skr13.54	Skr18.86	x
2015-12-31	Skr7.73	Skr18.86	x
2016-12-31	Skr8.97	Skr18.86	x
2017-12-31	Skr9.50	Skr18.86	x
2018-12-31	Skr13.57	Skr18.86	x
2019-12-31	Skr19.98	Skr18.86	x
2020-12-31	Skr16.24	Skr18.86	x
2021-12-31	Skr10.19	Skr18.86	x
2022-12-31	Skr5.64	Skr18.86	x
2023-12-31	Skr1.71	Skr18.86	x
2024-12-31	Skr-3.66	Skr18.86	x
2025-12-31	Skr14.17	Skr18.86	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Orexo AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -26.46%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -499.23%
• Asset Turnover: 0.02x
• Equity Multiplier: 2.66x
Recent ROE (-26.46%) is above the historical average (-41.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2002	-81.53%	-702.57%	0.09x	1.30x	Skr-23.35 Million
2003	-76.90%	-129.18%	0.47x	1.26x	Skr-31.18 Million
2004	-20.07%	-18.39%	0.82x	1.33x	Skr-23.89 Million
2005	-12.76%	-69.36%	0.17x	1.10x	Skr-77.14 Million
2006	-10.16%	-24.97%	0.35x	1.17x	Skr-65.38 Million
2008	-18.09%	-44.16%	0.33x	1.23x	Skr-160.03 Million
2009	-17.88%	-41.54%	0.36x	1.18x	Skr-152.95 Million
2010	-19.06%	-42.40%	0.30x	1.52x	Skr-136.07 Million
2011	-126.01%	-196.38%	0.37x	1.76x	Skr-423.12 Million
2012	-44.91%	-26.32%	0.68x	2.52x	Skr-104.98 Million
2013	-95.96%	-36.09%	0.56x	4.78x	Skr-171.08 Million
2014	-12.44%	-9.92%	0.47x	2.69x	Skr-102.09 Million
2015	-74.30%	-30.77%	0.63x	3.81x	Skr-224.63 Million
2016	9.35%	4.11%	0.69x	3.28x	Skr-2.03 Million
2017	7.05%	3.60%	0.64x	3.05x	Skr-9.71 Million
2018	28.96%	17.61%	0.61x	2.70x	Skr90.29 Million
2019	31.02%	25.94%	0.56x	2.13x	Skr148.46 Million
2020	-15.11%	-12.72%	0.54x	2.21x	Skr-140.25 Million
2021	-63.93%	-39.56%	0.44x	3.64x	Skr-258.46 Million
2022	-91.59%	-28.45%	0.56x	5.72x	Skr-196.99 Million
2023	-217.83%	-20.08%	0.81x	13.35x	Skr-134.19 Million
2024	0.00%	-34.41%	0.99x	0.00x	Skr-190.37 Million
2025	-26.46%	-499.23%	0.02x	2.66x	Skr-178.86 Million

Industry Comparison

This section compares Orexo AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $633,824,050
Average return on equity (ROE) among peers: -70.67%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Orexo AB (ORX)	Skr490.60 Million	-81.53%	1.66x	$70.45 Million
BioGaia AB (publ) (BIOG-B)	$463.89 Million	38.92%	0.24x	$1.26 Billion
Enzymatica publ AB (ENZY)	$-901.48K	0.00%	0.00x	$66.35 Million
Enorama Pharma AB (ERMA)	$7.18 Million	-344.33%	4.93x	$2.25 Million
Gabather AB (publ) (GABA)	$3.44 Million	-248.55%	0.96x	$1.04 Million
Klaria Pharma Holding AB (KLAR)	$-452.69K	0.00%	0.00x	$23.19 Million
Moberg Pharma AB (publ) (MOB)	$201.49 Million	-5.64%	0.35x	$58.17 Million
Nanexa AB (NANEXA)	$16.96 Million	-37.43%	0.21x	$60.08 Million
Newbury Pharmaceuticals AB (NEWBRY)	$49.38 Million	-39.35%	0.48x	$4.48 Million
Swedish Orphan Biovitrum AB (publ) (SOBI)	$4.96 Billion	0.36%	0.35x	$15.91 Billion

About Orexo AB

ST:ORX Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$70.45 Million

Skr654.63 Million SEK

Market Cap Rank

#20535 Global

#367 in Sweden

Share Price

Skr18.86

Change (1 day)

-0.32%

52-Week Range

Skr13.80 - Skr41.60

All Time High

Skr85.70